Compile Data Set for Download or QSAR
Report error Found 500 Enz. Inhib. hit(s) with all data for entry = 9158
LigandPNGBDBM445930(US10669240, Compound 1329)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445759(US10669240, Compound 55)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445802(US10669240, Compound 98)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445829(US10669240, Compound 1141)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445828(US10669240, Compound 1116)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445831(US10669240, Compound 1153)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445743(US10669240, Compound 39)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445890(US10669240, Compound 1288)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445919(US10669240, Compound 1317)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445788(US10669240, Compound 84)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445783(US10669240, Compound 79)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445769(US10669240, Compound 65)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445730(US10669240, Compound 26)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445767(US10669240, Compound 63)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445805(US10669240, Compound 101)
Affinity DataEC50:  1nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445757(US10669240, Compound 53)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445752(US10669240, Compound 48)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445758(US10669240, Compound 54)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445888(US10669240, Compound 1286)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445713(US10669240, Compound 9)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445885(US10669240, Compound 1283)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445786(US10669240, Compound 82)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445944(US10669240, Compound 1343)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445782(US10669240, Compound 78)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445732(US10669240, Compound 28)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445731(US10669240, Compound 27)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445768(US10669240, Compound 64)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445775(US10669240, Compound 71)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445935(US10669240, Compound 1334)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445761(US10669240, Compound 57)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445804(US10669240, Compound 100)
Affinity DataEC50:  2nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM445829(US10669240, Compound 1141)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445830(US10669240, Compound 1152)
Affinity DataEC50:  3nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445771(US10669240, Compound 67)
Affinity DataEC50:  3nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445931(US10669240, Compound 1330)
Affinity DataEC50:  3nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445760(US10669240, Compound 56)
Affinity DataEC50:  3nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445762(US10669240, Compound 58)
Affinity DataEC50:  3nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445929(US10669240, Compound 1328)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445750(US10669240, Compound 46)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445840(US10669240, Compound 1195)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445789(US10669240, Compound 85)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445742(US10669240, Compound 38)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM445759(US10669240, Compound 55)
Affinity DataIC50: 4nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445806(US10669240, Compound 102)
Affinity DataEC50:  4nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445863(US10669240, Compound 1261)
Affinity DataEC50:  5nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445824(US10669240, Compound 349)
Affinity DataEC50:  5nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445766(US10669240, Compound 62)
Affinity DataEC50:  5nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445869(US10669240, Compound 1267)
Affinity DataEC50:  5nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM445758(US10669240, Compound 54)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines were generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a W...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

LigandPNGBDBM445807(US10669240, Compound 103)
Affinity DataEC50:  5nMAssay Description:SH-SY5Y cells are cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptamycin. Two days before treat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details
US Patent

Displayed 1 to 50 (of 500 total ) | Next | Last >>
Jump to: